Azathioprine immunosuppression and disease modification in Parkinson's disease (AZA-PD): a randomised double-blind placebo-controlled phase II trial protocol (2020)
Attributed to:
The NET-PDD study: defining the roles of NEuroinflammation and Tau aggregation in Parkinson's Disease Dementia
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1136/bmjopen-2020-040527
PubMed Identifier: 33234645
Publication URI: http://europepmc.org/abstract/MED/33234645
Type: Journal Article/Review
Parent Publication: BMJ Open
Issue: 11
ISSN: 2044-6055